<DOC>
	<DOCNO>NCT01845259</DOCNO>
	<brief_summary>Metabolic disturbance , obesity life-shortening cardiovascular morbidity major clinical problem among antipsychotic-treated patient . Especially two efficacious antipsychotic , clozapine olanzapine , cause weight gain metabolic disturbance rarely replace drug due effectiveness compound . Glucagon-like peptide 1 ( GLP-1 ) improve glycemic control among patient type 2 diabetes . The study investigate whether beneficial effect GLP-1 analogue glycemic control type 2 diabetic patient , extended population non-diabetic , dysglycemic psychiatric patient , receive antipsychotic medical treatment .</brief_summary>
	<brief_title>Does GLP-1 Receptor Agonist Change Glucose Tolerance Antipsychotic-treated Patients ?</brief_title>
	<detailed_description>Statistical analysis : Power calculation : A sample size 96 participant ( 48 group ) estimate , two-sided t-testing , α 5 % power 90 % . The power calculation base primary outcome measurement : Change glucose tolerance . The glucose tolerance estimate total Area Under Curve ( AUC ) follow 4-hour 75-g . Oral Glucose Tolerance Test ( OGTT ) . The expected mean total AUC plasma glucose excursion follow 4-hour 75-g. OGTT estimate 1695 ( SD 158 ) 1800 ( SD 158 ) 16 week treatment liraglutide liraglutide placebo group , respectively . The difference total AUC base unpublished data individual without Impaired Glucose Tolerance ( IGT ) follow 4-hour 75-g. OGTT baseline study : `` The Impact Liraglutide Glucose Tolerance Risk Type 2 Diabetes Women With Previous Pregnancy-induced Diabetes '' . ( 1 ) Procedure : All analysis carry treatment group still blind label `` treatment group A '' `` treatment group B '' . Before divide participant group A group B , statistical plan complete uploaded clinicaltrials.gov , data set lock . The final unblinding treatment group ( liraglutide liraglutide placebo ) , carry statistical analysis perform . All analysis perform use SAS 9.4 , α set 0.05 two-sided testing . All efficacy analyse perform use modify intention-to-treat principle . All participant randomize , receive least one dose trial compound ( liraglutide liraglutide placebo ) least one assessment baseline include efficacy analysis . All safety analysis perform intent-to-treat sample include participant , randomize receive least one dose trial compound ( liraglutide liraglutide placebo ) . Primary endpoint : The primary endpoint change glucose tolerance follow 4-hour 75-g. OGTT week 0 week 16 . During 4-hour 75-g. OGTT , blood sample fixed time point : -15 , -10 , 0 , 5 , 10 , 15 , 20 , 30 , 40 , 50 , 60 , 90 , 120 , 150 , 180 , 240 minute . An analysis covariance ( ANCOVA ) use analyze change glucose tolerance week 0 week 16 use mixed model analysis plasma glucose level liraglutide liraglutide placebo group , respectively . In case relevant baseline difference two group , demographic , illness treatment parameter include model fix effect together baseline value OGTTs covariate . Secondary endpoint : Blood also sample analysis C-peptide , glucagon incretin hormone response glucose load fix time point OGTT . Change secretion C-peptide , glucagon incretin hormone week 0 week 16 also evaluate use mixed model ANCOVA analyse liraglutide liraglutide placebo group , respectively . In case relevant baseline difference two group , demographic , illness treatment parameter include model fix effect together baseline value relevant variable covariate . Most secondary endpoint repeat every 4 week . Few secondary endpoint repeat week 0 16 . For repeated measurement mixed model ANCOVA analyse use analyze mean change continuous outcome week 0 week 16 liraglutide liraglutide placebo group , respectively . In case relevant baseline difference two group , demographic , illness treatment parameter include model fix effect together baseline value relevant variable covariate . Change categorical outcome week 0 week 16 analyze use mixed model logistic regression fix effect covariates describe continuous outcome . For secondary endpoint without repeated measurement , miss data imputation make use Multiple Imputation Chained Equations ( MICE ) . For continuous outcome without repeated measurement , outcome analyze use ANCOVA detect difference liraglutide liraglutide placebo group . In model baseline demographic , illness treatment parameter include . Categorical outcomes without repeat measurement analyze use multiple mixed effect logistic regression analysis model , baseline demographic , illness treatment parameter include . Subgroup sensitivity analysis : Subgroup sensitivity analysis perform assess robustness primary analysis . These analysis perform use regression analysis continuous outcome logistic regression categorical outcome . The analysis consider clinically mechanistically relevant baseline intra-treatment variable , include : - Gender - Smoking - Antipsychotics ( clozapine v olanzapine ; monopharmacy v polypharmacy antipsychotic medication ) - Lipid profile - Liver function - Different group dysglycaemia : 1 . HbA1c : 43 mmol/mol ≤ HbA1c ≤ 47 mmol/mol , vs 2 . Impaired fast glucose ( IFG ) : Fasting plasma glucose ( FPG ) : 6.1 mmol/l ≤ FPG ≤ 6.9 mmol/l HbA1c &lt; 48 mmol/mol , vs 3 . Impaired glucose tolerance ( IGT ) : two-hour plasma glucose 75-g oral glucose tolerance test &gt; 7.8 mmol/l FPG &lt; 7.0 mmol/l HbA1c &lt; 48 mmol/mol - IGT &lt; 11 mmol/l v IGT &gt; 11 mmol/l - Liraglutide treatment ( 1.2 mg v 1.8 mg liraglutide ) - Weight - Add-on psychotropic drugs/classes ( antidepressant , anxiolytic etc . vs add-on ) - Antihypertensive treatment v antihypertensive treatment - Lipid lower treatment v lipid lower treatment - Changes antipsychotic medication ( &gt; 20 % change dose v &lt; 20 % change dose v change dose clozapine olanzapine , respectively ) - Inhalation steroid v inhalation steroid - Body composition - Insulin resistance - Beta-cell function - Incretin hormones - Psychopathologic rating scale - Alcohol consumption - Length disease - Diagnosis ( schizophrenia v schizotypal disorder v paranoid psychosis ) - Side effect - Serious adverse event Reference List 1 . Foghsgaard S , Vedtofte L , Mathiesen ER et al . The effect glucagon-like peptide-1 receptor agonist glucose tolerance woman previous gestational diabetes mellitus : protocol investigator-initiated , randomised , placebo-controlled , double-blinded , parallel intervention trial . BMJ Open 2013 ; 3 ( 10 ) : e003834 .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Informed oral write consent Diagnosed schizophrenia , schizotypal disorder paranoid psychosis accord criterion ICD10 ( International Classification Diseases , World Health Organization ) DSMIV ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition , American Psychiatric Association ) stable antipsychotic treatment either clozapine olanzapine least 6 month ( without dose change least 30 day ) Stable comedications least 30 day . Age ≥18 year ≤65 year Stable weight ( define less 5 % change weight last 3 month inclusion ) BMI ≥27 kg/m2 Dysglycaemia ( IFG , i.e . fast plasma glucose level 6.1 mmol/L 6.9 mmol/L IGT , i.e . twohour glucose level &gt; 7.8 mmol/L 75g oral glucose tolerance test fast plasma glucose le 7.0 mmol/L HbA1c &lt; 48 mmol/mol HbA1c : 43 mmol/mol ≤ HbA1c ≤ 47 mmol/mol ) Compulsory treatment Females child bear potential pregnant , breastfeed intention become pregnant use adequate contraceptive measure Subjects treat corticosteroid hormone therapy ( except estrogen ) Any active substance abuse dependence past 6 month ( except nicotine ) Impaired hepatic function ( liver transaminase &gt; 2 time upper normal limit ) Impaired renal function ( secreatinine &gt; 150 μM and/or macroalbuminuria ) Impaired pancreatic function ( acute chronic pancreatitis and/or amylase &gt; 2 time upper normal limit ) Cardiac problem define decompensated heart failure ( NYHA class III IV ) , unstable angina pectoris and/or myocardial infarction within last 12 month Uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg , diastolic blood pressure &gt; 100 mmHg ) Any condition investigator feel would interfere trial participation Receiving investigational drug within last 3 month Use weightlowering pharmacotherapy within precede 3 month Type 1 2 diabetes HbA1c &gt; 6.5 % Also group healthy control ( n=10 ) baseline examination do . The healthy control match participant regard gender , BMI age . The inclusion exclusion criterion apply control , except participant allow know psychiatric illness , receive antipsychotic medication , family history type 2 diabetes ( 2 generation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>